FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Burnett Patrick					2. Issuer Name and Ticker or Trading Symbol Arcutis Biotherapeutics, Inc. [ARQT]								ck all applic Directo	cable)	g Pers	son(s) to Iss 10% Ov Other (s	ner		
(Last)	(F	irst)	(Middle)		3. Da	Date of Earliest Transaction (Month/Day/Year)								┪ ′	below)	See R	om or	below)	
C/O ARCUTIS BIOTHERAPEUTICS, INC.					03/03/2021									See R	emar	KS			
3027 TOWNSGATE ROAD, SUITE 300																			
(Street) WESTLAKE VILLAGE CA 91361				4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person								
(City)	(S	tate)	(Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,		Code (I	Transaction Disposed Of (D) (Instr. 3, 4) Code (Instr. 5)			5. Amour Securitie Beneficia Owned F	s ally following	Form (D) or	i. Ownership Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) or (D)		Price	Reported Transact (Instr. 3 a	ion(s)		(Instr. 4)	
Common Stock 03/03/3					/2021 A 9,500 ⁽¹⁾ A		\$ <mark>0</mark>	9,500(2)(3)			D								
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	ate, Tr	Code (Inst				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
	Code V (A) (D) Exercisable Date Expiration Date Title Shares																		
Stock Option (Right to Buy)	\$32.44	03/03/2021			A		28,800		(4)	C	3/03/2031	Common Stock	28	3,800	\$0.00	28,800)	D	

Explanation of Responses:

- 1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 3 of each year, beginning March 3, 2022, subject to the Reporting Person's continued service to the Issuer.
- 2. Includes 9,500 RSUs.
- 3. Excludes 33,500 performance-based RSUs previously reported on Table I of Form 4 filed on 8/5/2020 which have not yet vested.
- 4. 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 3, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Remarks:

Senior Vice President and Chief Medical Officer

/s/ John W. Smither, as

Attorney-in-Fact for Patrick

Burnett

** Signature of Reporting Person Date

03/05/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.